Abstract 3773
Background
It is internationally recognised that centralisation of specialist cancer services results in improved oncologic outcomes, particularly for rare cancers. Ireland’s oncology services were formally centralised into 8 high volume cancer centres in 2007. We sought to identify changes in the utilisation of cancer treatment modalities and outcomes for patients with hepatobiliary cancers in Ireland pre and post centralisation.
Methods
Following local ethics board approval, anonymised patient data was provided by the National Cancer Registry of Ireland (NCRI) regarding all cases of hepatocellular cancer (HCC), cholangiocarcinoma and gallbladder cancers (ICD10: C22, C23 and C24) diagnosed in Ireland between 2000 – 2016. Data analysis was completed in collaboration with the NCRI.
Results
Data from 5733 patients with cholangiocarcinoma, gallbladder cancer and HCC over 16 years were analysed (Table). Similar rates of resection of all cancers were identified (21% pre 2008 and 24% from 2008 -2016). Overall 5-year survival for all cancers evaluated was significantly higher (non-overlapping CI) from 2008 -2016 - 16.1% (95% CI 14.4-17.8%) compared to pre 2008 - 12.6% (95% CI 11.0-14.4%). Despite similar rates of resection, 5-year survival rates for all resected cancers was significantly improved from 2008 - 2016 - 46.0% (95% CI 41.3-50.6%) vs 35.7% (95% CI 30.7-40.6%) prior to this. The most significant changes in use of treatment modality over the time course studied was the number of patients who received chemotherapy only (9% pre 2008 and 19% 2008 -2016, p < 0.01) and the significant increase in the number of patients who underwent adjuvant treatment (21% pre 2008 versus 42% from 2008 - 2016, p < 0.01).Table:
740P
Cancer Subtypes | 2000-2007 | 2008-2016 |
Cholangiocarcinoma | 38% (782) | 41% (1519) |
Hepatocellular Carcinoma | 17% (346) | 21% (780) |
Gallbladder | 19% (379) | 13% (497) |
Unspecified Subtype | 26% (537) | 24% (893) |
Total | 2044 | 3689 |
Conclusions
The establishment of national cancer centres in Ireland in 2007 was associated with improvement in 5-year survival for patients with hepatobiliary malignancies and with increased utilisation of systemic therapy in the advanced and adjuvant settings.
Clinical trial identification
Editorial acknowledgement
We would like to thank all the team at the National Cancer Registry of Ireland for their hard work collecting the data.
Legal entity responsible for the study
St. James’ Hospital, Dublin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3392 - Post-hoc analysis of the nintedanib exposure-response relationships in the CHIVA trial in advanced ovarian cancer: (a GINECO study)
Presenter: Skerdi HAVIARI
Session: Poster Display session 2
Resources:
Abstract
714 - The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian insufficiency in patient with malignant ovarian germ cell tumors
Presenter: Min Kyu Kim
Session: Poster Display session 2
Resources:
Abstract
1753 - Ex vivo cytotoxicity and in vivo antitumor activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer
Presenter: Kosei Hasegawa
Session: Poster Display session 2
Resources:
Abstract
3739 - Mutational landscapes and tumor mutational burden expression in endometrial cancer
Presenter: Yingli Zhang
Session: Poster Display session 2
Resources:
Abstract
2109 - Clinical features and frequency of mismatch repair protein deficiency in ovarian clear cell and endometrioid carcinoma patients.
Presenter: Kazuhiro Takehara
Session: Poster Display session 2
Resources:
Abstract
4554 - Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer
Presenter: Lea Moukarzel
Session: Poster Display session 2
Resources:
Abstract
3645 - Cancer-specific survival with or without adjuvant chemotherapy in high-risk stage I endometrial cancer
Presenter: Jenny Ko
Session: Poster Display session 2
Resources:
Abstract
3394 - Pembrolizumab in Patients with MSI-H Advanced Endometrial Cancer from the KEYNOTE-158 Study
Presenter: David Omalley
Session: Poster Display session 2
Resources:
Abstract
3388 - Who drops out of cervical cancer screening? Results from the EDIFICE 6 survey
Presenter: Thibault de La Motte Rouge
Session: Poster Display session 2
Resources:
Abstract
2485 - Identification of a RNA-Seq Based Signature to Improve Prognostic for Uterine Sarcoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 2
Resources:
Abstract